tetano
Editor, Senior Moderator
Int J Hematol
. 2022 Jun 6.
doi: 10.1007/s12185-022-03387-9. Online ahead of print.
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria
Yuya Kamura[SUP] 1 [/SUP], Tatsuhiro Sakamoto[SUP] 1 2 [/SUP], Yasuhisa Yokoyama[SUP] 1 2 [/SUP], Hidekazu Nishikii[SUP] 1 2 [/SUP], Mamiko Sakata-Yanagimoto[SUP] 1 2 3 [/SUP], Shigeru Chiba[SUP] 1 2 [/SUP], Naoshi Obara[SUP] 4 5 [/SUP]
Affiliations
Abstract
Autoimmune and complement-related hematological side effects have been observed with messenger ribonucleic acid (mRNA) vaccines. Here, we report the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). We reviewed the medical records of seventeen patients with PNH visiting the University of Tsukuba Hospital who had received two doses of the SARS-CoV-2 mRNA vaccine between May 2021 and November 2021. Twelve patients were being treated with complement inhibitors. The median age of all patients was 62 years (range 29-89 years).; six were males and eleven were females. Fourteen patients received the BNT162b2 vaccine (Pfizer/BioNTech) and three received the mRNA-1273 vaccine (Moderna). The median percentages of PNH clones in erythrocytes and granulocytes were 37.61% (range 8.11-85.71%) and 59.73% (range 3.76-97.82%), respectively. Of the twelve patients receiving complement inhibitors, only one had a hemolytic reaction after vaccination, but it did not meet the definition of breakthrough hemolysis. By contrast, hemolytic attacks were observed in two of the five untreated patients with PNH, and one of them required a blood transfusion. Appropriate administration of complement inhibitors to patients with PNH may prevent hemolysis induced by SARS-CoV-2 mRNA vaccination.
Keywords: Complement inhibitor; Hemolysis; PNH; SARS-CoV-2; mRNA vaccine.
. 2022 Jun 6.
doi: 10.1007/s12185-022-03387-9. Online ahead of print.
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria
Yuya Kamura[SUP] 1 [/SUP], Tatsuhiro Sakamoto[SUP] 1 2 [/SUP], Yasuhisa Yokoyama[SUP] 1 2 [/SUP], Hidekazu Nishikii[SUP] 1 2 [/SUP], Mamiko Sakata-Yanagimoto[SUP] 1 2 3 [/SUP], Shigeru Chiba[SUP] 1 2 [/SUP], Naoshi Obara[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35668275
- DOI: 10.1007/s12185-022-03387-9
Abstract
Autoimmune and complement-related hematological side effects have been observed with messenger ribonucleic acid (mRNA) vaccines. Here, we report the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). We reviewed the medical records of seventeen patients with PNH visiting the University of Tsukuba Hospital who had received two doses of the SARS-CoV-2 mRNA vaccine between May 2021 and November 2021. Twelve patients were being treated with complement inhibitors. The median age of all patients was 62 years (range 29-89 years).; six were males and eleven were females. Fourteen patients received the BNT162b2 vaccine (Pfizer/BioNTech) and three received the mRNA-1273 vaccine (Moderna). The median percentages of PNH clones in erythrocytes and granulocytes were 37.61% (range 8.11-85.71%) and 59.73% (range 3.76-97.82%), respectively. Of the twelve patients receiving complement inhibitors, only one had a hemolytic reaction after vaccination, but it did not meet the definition of breakthrough hemolysis. By contrast, hemolytic attacks were observed in two of the five untreated patients with PNH, and one of them required a blood transfusion. Appropriate administration of complement inhibitors to patients with PNH may prevent hemolysis induced by SARS-CoV-2 mRNA vaccination.
Keywords: Complement inhibitor; Hemolysis; PNH; SARS-CoV-2; mRNA vaccine.